Lymphocytes upregulate CD36 in adipose tissue and liver

References

• Urban BC, Willcox N, Roberts DJ. A role for CD36 in the regulation of dendritic cell function. Proc Natl Acad Sci USA. 2001;98:8750–8755.
   PubMed Web of Science ®Google Scholar
• Corcoran L, Vremec D, Febbraio M, et al. Differential regulation of CD36 expression in antigen-presenting cells: Oct- 2dependence in B lymphocytes but not dendritic cells or macrophages. Int Immunol. 2002;14:1099–1104.
   PubMed Web of Science ®Google Scholar
• Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009;2:re3.
   PubMed Web of Science ®Google Scholar
• Pepino MY, Kuda O, Samovski D, et al. Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr. 2014;34:281–303.
   PubMed Web of Science ®Google Scholar
• Zamora C, Cantó E, Nieto JC, et al. Functional consequences of platelet binding to T lymphocytes in inflammation. J Leukoc Biol. 2013;94:521–529.
   PubMed Web of Science ®Google Scholar
• Cipolletta D, Feuerer M, Li A, et al. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature. 2012;486:549–553.
   PubMed Web of Science ®Google Scholar
• Geys L, Vranckx C, Lijnen HR, et al. CD36 deficiency blunts effects of diet on regulatory T cells in murine gonadal adipose tissue and mesenteric lymph nodes. Cell Immunol. 2015;298:33–36.
   PubMed Web of Science ®Google Scholar
• Han SJ, Glatman Zaretsky A, Andrade-Oliveira V, et al. White adipose tissue is a reservoir for memory T cells and promotes protective memory responses to infection. Immunity. 2017;47:1154–1168.e6.
   PubMed Web of Science ®Google Scholar
• Pan Y, Tian T, Park CO, et al. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. Nature. 2017 Mar 9;543(7644):252–256.
   PubMed Web of Science ®Google Scholar
• Bonen A, Tandon NN, Glatz JF, et al. The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes. Int J Obes (Lond). 2006;30:877–883.
   PubMed Web of Science ®Google Scholar
• Kennedy DJ, Kuchibhotla S, Westfall KM, et al. A CD36-dependent pathway enhances macrophage and adipose tissue inflammation and impairs insulin signalling. Cardiovasc Res. 2011;89:604–613.
   PubMed Web of Science ®Google Scholar
• Cai L, Wang Z, Ji A, et al. Scavenger receptor CD36 expression contributes to adipose tissue inflammation and cell death in diet-induced obesity. PLoS One. 2012;7:e36785.
   PubMed Web of Science ®Google Scholar
• Sheedy FJ, Grebe A, Rayner KJ, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol. 2013;14:812–820.
   PubMed Web of Science ®Google Scholar
• Yang J, Park KW, Cho S. Inhibition of the CD36 receptor reduces visceral fat accumulation and improves insulin resistance in obese mice carrying the BDNF-Val66Met variant. J Biol Chem. 2018;293:13338–13348.
   PubMed Web of Science ®Google Scholar
• Ye H, Adane B, Khan N, et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue Niche. Cell Stem Cell. 2016;19:23–37.
   PubMed Web of Science ®Google Scholar
• Pascual G, Avgustinova A, Mejetta S, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 2017;541:41–45.
   PubMed Web of Science ®Google Scholar
• Ladanyi A, Mukherjee A, Kenny HA, et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018;37:2285–2301.
   PubMed Web of Science ®Google Scholar
• Smith J, Su X, El-Maghrabi R, et al. Opposite regulation of CD36 ubiquitination by fatty acids and insulin: effects on fatty acid uptake. J Biol Chem. 2008;283:13578–13585.
   PubMed Web of Science ®Google Scholar
• Shirakawa K, Yan X, Shinmura K, et al. Obesity accelerates T cell senescence in murine visceral adipose tissue. J Clin Invest. 2016;126:4626–4639.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Højlund K, Andersen M, et al. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care. 2008;31:328–334.
   PubMed Web of Science ®Google Scholar
• Handberg A, Skjelland M, Michelsen AE, et al. Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability. Stroke. 2008;39:3092–3095.
   PubMed Web of Science ®Google Scholar
• Alkhatatbeh MJ, Mhaidat NM, Enjeti AK, et al. The putative diabetic plasma marker, soluble CD36, is non-cleaved, non-soluble and entirely associated with microparticles. J Thromb Haemost. 2011;9:844–851.
   PubMed Web of Science ®Google Scholar
• Shiju TM, Mohan V, Balasubramanyam M, et al. Soluble CD36 in plasma and urine: a plausible prognostic marker for diabetic nephropathy. J Diabetes Complications. 2015;29:400–406.
   PubMed Web of Science ®Google Scholar